Home › Funds › SR ONE CAPITAL MANAGEMENT, LP › MLYS

SR ONE CAPITAL MANAGEMENT, LP position in MLYS

MINERALYS THERAPEUTICS INC · Health Care

SR ONE CAPITAL MANAGEMENT, LP reported holding 1,563,966 shares of MLYS (MINERALYS THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$42.2M, representing 4.06% of its reported portfolio and ranking #9 among its reported holdings. SR ONE CAPITAL MANAGEMENT, LP has disclosed MLYS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.56M sh
Reported value held$42.20M
Portfolio Weight4.06%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How SR ONE CAPITAL MANAGEMENT, LP's MLYS position evolved

SR ONE CAPITAL MANAGEMENT, LP first disclosed a stake in MLYS in Q3 2023 at 1,794,600 shares (US$17.1M). The position peaked in Q3 2025 at 2,113,933 shares, worth US$80.2M. Across 12 filings, SR ONE CAPITAL MANAGEMENT, LP increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 1,563,966 shares valued at US$42.2M. Notable position changes include a 55% increase in Q1 2025 (shares fell 15% over the following quarter), a 32% trim in Q3 2025 (shares fell 4% over the following quarter), a 26% trim in Q4 2025 (shares fell 25% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.79M $17.07M New
Q4 2023 1.79M $15.43M Hold
Q1 2024 2.02M $26.04M Add
Q2 2024 2.02M $23.60M Hold
Q3 2024 2.02M $24.42M Hold
Q4 2024 2.02M $24.83M Hold
Q1 2025 3.13M $49.67M Add
Q2 2025 3.13M $42.32M Hold
Q3 2025 2.11M $80.16M Reduce
Q4 2025 1.56M $56.76M Reduce
Q1 2026 1.56M $42.37M Hold
Q2 2026 1.56M $42.20M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MLYS and 13F data

MLYS (MINERALYS THERAPEUTICS INC) is a Health Care company. 53 other funds we track also report a position in MLYS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$207.6M), Catalys Pacific, LLC (US$196.0M), Samsara BioCapital, LLC (US$158.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MLYS

All MLYS fund holders →

FAQ

How long has SR ONE CAPITAL MANAGEMENT, LP held MLYS?

SR ONE CAPITAL MANAGEMENT, LP has disclosed MLYS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is SR ONE CAPITAL MANAGEMENT, LP's current position in MLYS?

As of Q2 2026, SR ONE CAPITAL MANAGEMENT, LP holds 1.56M shares of MLYS (MINERALYS THERAPEUTICS INC), valued at $42.20M, representing 4.06% of its reported portfolio and ranking #9.

Has SR ONE CAPITAL MANAGEMENT, LP been buying or selling MLYS?

In the latest 13F filing (Q2 2026), SR ONE CAPITAL MANAGEMENT, LP held unchanged its position in MLYS. The position peaked in Q3 2025 at 2.11M shares.

Which other funds hold MLYS?

Other major institutional holders of MLYS include RA CAPITAL MANAGEMENT, L.P., Catalys Pacific, LLC, Samsara BioCapital, LLC, among 53 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.